Secukinumab in Active Non-segmental Vitiligo

NCT05676333 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

8

Enrollment

OTHER

Sponsor class

Conditions

Vitiligo
Secukinumab

Interventions

DRUG: Secukinumab

Sponsor

University Hospital, Ghent

Collaborators

[object Object]